Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2013
January 2013, Vol 4, No 1
January 2013, Vol 4, No 1
Ziv-Aflibercept: A New Option for the Treatment of Patients with Metastatic Colorectal Cancer Resistant to or Progressing After an Oxaliplatin-Containing Regimen
By
Lynne Lederman, PhD, Medical Writer
Drug Updates
January 2013, Vol 4, No 1
On August 3, 2012, the US Food and Drug Administration (FDA) approved ziv-aflibercept (Zaltrap) for use in combination with a FOLFIRI chemotherapy regimen to treat adults with mCRC that is resistant to or has progressed after an oxaliplatin-containing regimen.
Read Article
ATLAS: Ten Years of Tamoxifen Superior to 5 Years
By
Audrey Andrews
Breast Cancer
January 2013, Vol 4, No 1
San Antonio, TX—For the treatment of estrogen receptor (ER)-positive early breast cancer, 10 years of treatment with tamoxifen yields better outcomes than 5 years of treatment, according to an analysis from the international ATLAS study that was presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.
Read Article
Investigational CDK Inhibitor Extends Remission Time
Breast Cancer
January 2013, Vol 4, No 1
San Antonio, TX—The addition of an oral investigational agent to letrozole (Femara) for the treatment of estrogen receptor (ER)-positive metastatic breast cancer more than tripled the time spent in remission compared with endocrine therapy alone, according to a study reported at the CTRC-AACR San Antonio Breast Cancer Symposium.
Read Article
Axillary Ultrasound versus Sentinel Lymph Node Biopsy in Invasive Breast Cancer
By
Rosemary Frei, MSc
Breast Cancer
January 2013, Vol 4, No 1
Vancouver, BC—In the aftermath of the Z0011 study from the American College of Surgeons Oncology Group, oncology centers across the United States are reexamining their approach to axillary management in breast cancer.
Read Article
Breast-Conserving Surgery Underutilized
By
Audrey Andrews
Breast Cancer
January 2013, Vol 4, No 1
Vienna, Austria—Despite a robust response to neoadjuvant chemotherapy, which renders many early breast cancer tumors resectable, breast-conserving surgery is often overlooked in favor of mastectomy, according to an analysis of the Neo-ALLTO clinical trial, which was presented at the 2012 European Society for Medical Oncology Congress.
Read Article
Black Women with Invasive Node-Negative Breast Cancer Less Likely to Get Sentinel Lymph Node Biopsy for Axillary Staging, More Likely to Have Lymphedema
By
Phoebe Starr
Breast Cancer
January 2013, Vol 4, No 1
San Antonio, TX—Black women with clinically node-negative invasive breast cancer were less likely than white women to undergo sentinel lymph node biopsy (SLNB) for axillary staging and also were more likely to develop lymphedema, according to a study presented at the CTRC-AACR San Antonio Breast Cancer Symposium.
Read Article
Real-Time Performance Tracking Improves Patient Care at 64 Cancer Centers
By
Caroline Helwick
ASCO’s 1st Quality Care Symposium
,
ASCO
January 2013, Vol 4, No 1
San Diego, CA—A real-time performance tracking system that monitors adherence to quality care metrics significantly improved adherence to quality standards over a 4-year period for 64 cancer centers participating in the Rapid Quality Reporting System (RQRS) “beta test,” according to researchers who are pioneering the program.
Read Article
Multidisciplinary Palliative Care Team at Johns Hopkins Achieves Reduction in ICU Utilization, Cost
By
Caroline Helwick
ASCO’s 1st Quality Care Symposium
,
ASCO
January 2013, Vol 4, No 1
San Diego, CA—A multidisciplinary team approach for discussing end-of-life issues with patients reduces the use of the intensive care unit (ICU) without shortening survival time, researchers from the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University said at ASCO’s inaugural 2012 Quality Care Symposium.
Read Article
A Call for Transparency in Drug Pricing
Value-Based Care
,
VBCC Perspectives
January 2013, Vol 4, No 1
In the December 2012 issue of
Value-Based Cancer Care
(
VBCC
), several Editorial Board members addressed the recent events surrounding the cost of cancer drugs and the reduction of the price of ziv-aflibercept (Zaltrap).
VBCC
continued this discussion with Al B. Benson III, MD, FACP, FASCO.
Read Article
Genetic Testing with Oncotype DX for Women with DCIS Shown Cost-Effective in Independent Study
Health Economics
January 2013, Vol 4, No 1
San Antonio, TX—In determining the optimal treatment of ductal carcinoma in situ (DCIS), gene expression profiling using the Oncotype DX DCIS Score is more cost-effective than standard clinical assessment, primarily because it avoids radiotherapy for approximately 66% of these patients.
Read Article
Page 1 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma